tazobactam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| beta-lactamase inhibitors | 2572 | 89786-04-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 77 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 66.49 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 0.26 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 4.81 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.70 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.97 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 18, 2015 | EMA | MERCK SHARP & DOHME B.V. | |
| Oct. 22, 1993 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Thrombocytopenia | 111.06 | 19.03 | 117 | 8213 | 151040 | 63329652 |
| Sepsis | 92.51 | 19.03 | 107 | 8223 | 153016 | 63327676 |
| Acute kidney injury | 72.06 | 19.03 | 126 | 8204 | 263289 | 63217403 |
| Respiratory failure | 67.96 | 19.03 | 75 | 8255 | 101783 | 63378909 |
| Pyrexia | 67.77 | 19.03 | 173 | 8157 | 470305 | 63010387 |
| Multiple organ dysfunction syndrome | 62.56 | 19.03 | 55 | 8275 | 56697 | 63423995 |
| Renal failure | 60.80 | 19.03 | 76 | 8254 | 117576 | 63363116 |
| Pancytopenia | 58.90 | 19.03 | 68 | 8262 | 96865 | 63383827 |
| Eosinophilia | 56.68 | 19.03 | 36 | 8294 | 22720 | 63457972 |
| Leukopenia | 55.18 | 19.03 | 59 | 8271 | 77231 | 63403461 |
| Dermatitis exfoliative generalised | 50.65 | 19.03 | 19 | 8311 | 3788 | 63476904 |
| Disseminated intravascular coagulation | 49.60 | 19.03 | 31 | 8299 | 19020 | 63461672 |
| Toxic epidermal necrolysis | 48.44 | 19.03 | 34 | 8296 | 25300 | 63455392 |
| Septic shock | 47.80 | 19.03 | 51 | 8279 | 66578 | 63414114 |
| Rash maculo-papular | 43.58 | 19.03 | 35 | 8295 | 31861 | 63448831 |
| Platelet count decreased | 41.80 | 19.03 | 63 | 8267 | 116059 | 63364633 |
| Arthralgia | 39.24 | 19.03 | 13 | 8317 | 569697 | 62910995 |
| Rash morbilliform | 38.51 | 19.03 | 15 | 8315 | 3310 | 63477382 |
| Haemoglobin decreased | 37.62 | 19.03 | 68 | 8262 | 145417 | 63335275 |
| Tubulointerstitial nephritis | 36.40 | 19.03 | 26 | 8304 | 19877 | 63460815 |
| Pleural effusion | 35.59 | 19.03 | 52 | 8278 | 93158 | 63387534 |
| Nephropathy toxic | 34.06 | 19.03 | 19 | 8311 | 9460 | 63471232 |
| Drug reaction with eosinophilia and systemic symptoms | 33.73 | 19.03 | 31 | 8299 | 33805 | 63446887 |
| Blood creatinine increased | 33.53 | 19.03 | 49 | 8281 | 87795 | 63392897 |
| Febrile neutropenia | 32.72 | 19.03 | 57 | 8273 | 118392 | 63362300 |
| Drug ineffective | 32.26 | 19.03 | 55 | 8275 | 1044710 | 62435982 |
| Pseudomonal sepsis | 32.00 | 19.03 | 12 | 8318 | 2389 | 63478303 |
| Heparin-induced thrombocytopenia | 30.68 | 19.03 | 14 | 8316 | 4568 | 63476124 |
| Fatigue | 29.98 | 19.03 | 44 | 8286 | 887984 | 62592708 |
| Drug intolerance | 29.77 | 19.03 | 3 | 8327 | 308658 | 63172034 |
| Joint swelling | 29.58 | 19.03 | 4 | 8326 | 327662 | 63153030 |
| Agranulocytosis | 28.97 | 19.03 | 25 | 8305 | 25109 | 63455583 |
| Toxic skin eruption | 28.68 | 19.03 | 19 | 8311 | 12866 | 63467826 |
| Prothrombin time prolonged | 28.58 | 19.03 | 17 | 8313 | 9547 | 63471145 |
| Platelet count increased | 27.57 | 19.03 | 21 | 8309 | 17690 | 63463002 |
| Abdominal discomfort | 26.53 | 19.03 | 5 | 8325 | 320880 | 63159812 |
| Alopecia | 26.38 | 19.03 | 6 | 8324 | 337530 | 63143162 |
| Acute generalised exanthematous pustulosis | 26.25 | 19.03 | 17 | 8313 | 11082 | 63469610 |
| Linear IgA disease | 25.90 | 19.03 | 9 | 8321 | 1442 | 63479250 |
| White blood cell count decreased | 25.12 | 19.03 | 56 | 8274 | 139048 | 63341644 |
| Headache | 24.81 | 19.03 | 28 | 8302 | 633213 | 62847479 |
| Neutropenia | 24.67 | 19.03 | 64 | 8266 | 174941 | 63305751 |
| Leukocytosis | 24.38 | 19.03 | 23 | 8307 | 25912 | 63454780 |
| Anaemia | 23.40 | 19.03 | 88 | 8242 | 293342 | 63187350 |
| Stevens-Johnson syndrome | 23.21 | 19.03 | 22 | 8308 | 24928 | 63455764 |
| Aspergillus infection | 23.18 | 19.03 | 14 | 8316 | 8079 | 63472613 |
| Dizziness | 23.01 | 19.03 | 14 | 8316 | 429911 | 63050781 |
| Haemolytic anaemia | 22.70 | 19.03 | 15 | 8315 | 10110 | 63470582 |
| Brain oedema | 22.47 | 19.03 | 17 | 8313 | 14178 | 63466514 |
| Cytomegalovirus infection | 22.46 | 19.03 | 20 | 8310 | 20932 | 63459760 |
| Fall | 22.10 | 19.03 | 12 | 8318 | 392322 | 63088370 |
| Acinetobacter infection | 21.42 | 19.03 | 8 | 8322 | 1575 | 63479117 |
| Hypokalaemia | 21.27 | 19.03 | 44 | 8286 | 103760 | 63376932 |
| Product contamination microbial | 20.83 | 19.03 | 5 | 8325 | 214 | 63480478 |
| Acute respiratory distress syndrome | 20.47 | 19.03 | 20 | 8310 | 23514 | 63457178 |
| Hypotension | 19.48 | 19.03 | 79 | 8251 | 272525 | 63208167 |
| Cytarabine syndrome | 19.36 | 19.03 | 4 | 8326 | 85 | 63480607 |
| Unresponsive to stimuli | 19.31 | 19.03 | 23 | 8307 | 33793 | 63446899 |
| Pseudomembranous colitis | 19.25 | 19.03 | 9 | 8321 | 3103 | 63477589 |
| Streptococcal infection | 19.17 | 19.03 | 11 | 8319 | 5776 | 63474916 |
| Clostridial infection | 19.12 | 19.03 | 10 | 8320 | 4382 | 63476310 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Lymphocyte count abnormal | 113.74 | 16 | 33 | 11401 | 1165 | 34944332 |
| Tubulointerstitial nephritis | 90.29 | 16 | 66 | 11368 | 20958 | 34924539 |
| Acute kidney injury | 87.06 | 16 | 257 | 11177 | 304731 | 34640766 |
| Thrombocytopenia | 84.84 | 16 | 169 | 11265 | 156078 | 34789419 |
| Sepsis | 72.86 | 16 | 165 | 11269 | 166396 | 34779101 |
| Pyrexia | 71.78 | 16 | 255 | 11179 | 332758 | 34612739 |
| Platelet count decreased | 64.31 | 16 | 129 | 11305 | 119588 | 34825909 |
| Neutrophil count increased | 62.90 | 16 | 49 | 11385 | 17097 | 34928400 |
| Choroiditis | 58.78 | 16 | 20 | 11414 | 1195 | 34944302 |
| Neutropenia | 56.34 | 16 | 144 | 11290 | 156634 | 34788863 |
| Delusion of grandeur | 55.75 | 16 | 19 | 11415 | 1141 | 34944356 |
| Multiple organ dysfunction syndrome | 51.65 | 16 | 91 | 11343 | 76475 | 34869022 |
| Clostridial infection | 46.39 | 16 | 23 | 11411 | 3604 | 34941893 |
| Rhinalgia | 45.77 | 16 | 16 | 11418 | 1037 | 34944460 |
| Disseminated intravascular coagulation | 43.23 | 16 | 44 | 11390 | 21772 | 34923725 |
| Cholestasis | 42.23 | 16 | 48 | 11386 | 26900 | 34918597 |
| Leukopenia | 41.46 | 16 | 74 | 11360 | 62782 | 34882715 |
| Dizziness | 40.05 | 16 | 11 | 11423 | 218510 | 34726987 |
| Renal tubular necrosis | 39.32 | 16 | 36 | 11398 | 15644 | 34929853 |
| Septic shock | 39.22 | 16 | 78 | 11356 | 71756 | 34873741 |
| Agranulocytosis | 38.30 | 16 | 43 | 11391 | 23778 | 34921719 |
| Rash | 38.27 | 16 | 159 | 11275 | 222593 | 34722904 |
| Stevens-Johnson syndrome | 37.68 | 16 | 38 | 11396 | 18601 | 34926896 |
| Drug reaction with eosinophilia and systemic symptoms | 37.50 | 16 | 50 | 11384 | 32962 | 34912535 |
| Respiratory failure | 35.14 | 16 | 96 | 11338 | 108476 | 34837021 |
| Intraocular pressure increased | 32.83 | 16 | 21 | 11413 | 5362 | 34940135 |
| Heparin-induced thrombocytopenia | 32.09 | 16 | 21 | 11413 | 5574 | 34939923 |
| Nephropathy toxic | 31.76 | 16 | 29 | 11405 | 12559 | 34932938 |
| Affective disorder | 31.64 | 16 | 19 | 11415 | 4341 | 34941156 |
| Congenital pneumonia | 30.46 | 16 | 7 | 11427 | 95 | 34945402 |
| Clostridium difficile colitis | 29.85 | 16 | 31 | 11403 | 15699 | 34929798 |
| Renal failure | 29.67 | 16 | 102 | 11332 | 130455 | 34815042 |
| Eosinophilia | 28.68 | 16 | 39 | 11395 | 26183 | 34919314 |
| Blood creatinine increased | 27.80 | 16 | 81 | 11353 | 94895 | 34850602 |
| Uveitis | 26.47 | 16 | 21 | 11413 | 7514 | 34937983 |
| Lymphocyte count | 25.93 | 16 | 6 | 11428 | 84 | 34945413 |
| Death | 25.53 | 16 | 58 | 11376 | 397991 | 34547506 |
| Chills | 24.56 | 16 | 70 | 11364 | 80973 | 34864524 |
| Headache | 24.44 | 16 | 18 | 11416 | 200617 | 34744880 |
| Pneumonia staphylococcal | 24.10 | 16 | 14 | 11420 | 3010 | 34942487 |
| Alanine aminotransferase increased | 23.72 | 16 | 69 | 11365 | 80746 | 34864751 |
| Subclavian artery occlusion | 23.70 | 16 | 6 | 11428 | 125 | 34945372 |
| Spontaneous haematoma | 22.80 | 16 | 8 | 11426 | 524 | 34944973 |
| Transplant rejection | 22.65 | 16 | 22 | 11412 | 10289 | 34935208 |
| Haemodialysis | 22.26 | 16 | 22 | 11412 | 10504 | 34934993 |
| Hepatic failure | 21.91 | 16 | 40 | 11394 | 34491 | 34911006 |
| Acute respiratory distress syndrome | 21.68 | 16 | 34 | 11400 | 25935 | 34919562 |
| Autoimmune haemolytic anaemia | 21.31 | 16 | 15 | 11419 | 4481 | 34941016 |
| Rash erythematous | 21.27 | 16 | 33 | 11401 | 24944 | 34920553 |
| Eye pain | 21.12 | 16 | 24 | 11410 | 13438 | 34932059 |
| Dialysis | 21.10 | 16 | 22 | 11412 | 11186 | 34934311 |
| Arthralgia | 21.03 | 16 | 15 | 11419 | 170026 | 34775471 |
| Blood alkaline phosphatase increased | 20.92 | 16 | 37 | 11397 | 31138 | 34914359 |
| Lymphocyte count decreased | 20.83 | 16 | 31 | 11403 | 22591 | 34922906 |
| Pancytopenia | 20.43 | 16 | 73 | 11361 | 95084 | 34850413 |
| Organ failure | 20.24 | 16 | 11 | 11423 | 2080 | 34943417 |
| Gamma-glutamyltransferase increased | 20.01 | 16 | 35 | 11399 | 29196 | 34916301 |
| Aspartate aminotransferase increased | 20.00 | 16 | 58 | 11376 | 67725 | 34877772 |
| Schizophrenia | 20.00 | 16 | 19 | 11415 | 8647 | 34936850 |
| Respiratory distress | 19.77 | 16 | 39 | 11395 | 35626 | 34909871 |
| SARS-CoV-2 test positive | 19.70 | 16 | 16 | 11418 | 5917 | 34939580 |
| Rash maculo-papular | 19.39 | 16 | 34 | 11400 | 28417 | 34917080 |
| Drug eruption | 19.38 | 16 | 28 | 11406 | 19870 | 34925627 |
| Hepatic function abnormal | 19.36 | 16 | 44 | 11390 | 44319 | 34901178 |
| Dermatitis exfoliative | 18.13 | 16 | 16 | 11418 | 6623 | 34938874 |
| Blood bilirubin increased | 17.85 | 16 | 39 | 11395 | 38257 | 34907240 |
| Hepatocellular injury | 17.06 | 16 | 28 | 11406 | 22183 | 34923314 |
| Hepatic cytolysis | 16.52 | 16 | 22 | 11412 | 14474 | 34931023 |
| Weight increased | 16.43 | 16 | 5 | 11429 | 93028 | 34852469 |
| Anaphylactic reaction | 16.33 | 16 | 34 | 11400 | 32267 | 34913230 |
| Scar pain | 16.15 | 16 | 4 | 11430 | 76 | 34945421 |
| Visual acuity reduced | 16.13 | 16 | 23 | 11411 | 16126 | 34929371 |
| Nephritis | 16.04 | 16 | 10 | 11424 | 2441 | 34943056 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Acute kidney injury | 152.83 | 16.65 | 332 | 16071 | 519072 | 79208913 |
| Thrombocytopenia | 144.96 | 16.65 | 222 | 16181 | 265037 | 79462948 |
| Sepsis | 124.57 | 16.65 | 209 | 16194 | 269219 | 79458766 |
| Tubulointerstitial nephritis | 115.93 | 16.65 | 81 | 16322 | 38154 | 79689831 |
| Pyrexia | 96.36 | 16.65 | 332 | 16071 | 678377 | 79049608 |
| Renal failure | 85.03 | 16.65 | 150 | 16253 | 200818 | 79527167 |
| Septic shock | 84.82 | 16.65 | 115 | 16288 | 122686 | 79605299 |
| Multiple organ dysfunction syndrome | 83.64 | 16.65 | 113 | 16290 | 120133 | 79607852 |
| Eosinophilia | 80.53 | 16.65 | 70 | 16333 | 45275 | 79682710 |
| Leukopenia | 77.27 | 16.65 | 107 | 16296 | 116406 | 79611579 |
| Platelet count decreased | 71.85 | 16.65 | 137 | 16266 | 194527 | 79533458 |
| Drug reaction with eosinophilia and systemic symptoms | 70.29 | 16.65 | 76 | 16327 | 64168 | 79663817 |
| Neutropenia | 66.83 | 16.65 | 168 | 16235 | 287542 | 79440443 |
| Choroiditis | 65.38 | 16.65 | 20 | 16383 | 1361 | 79726624 |
| Clostridial infection | 61.98 | 16.65 | 28 | 16375 | 5686 | 79722299 |
| Respiratory failure | 61.49 | 16.65 | 123 | 16280 | 180788 | 79547197 |
| Nephropathy toxic | 61.27 | 16.65 | 43 | 16360 | 20376 | 79707609 |
| Arthralgia | 60.72 | 16.65 | 21 | 16382 | 571782 | 79156203 |
| Delusion of grandeur | 60.47 | 16.65 | 19 | 16384 | 1413 | 79726572 |
| Dizziness | 60.07 | 16.65 | 17 | 16386 | 526424 | 79201561 |
| Rash maculo-papular | 59.01 | 16.65 | 65 | 16338 | 56013 | 79671972 |
| Disseminated intravascular coagulation | 57.02 | 16.65 | 52 | 16351 | 35790 | 79692195 |
| Heparin-induced thrombocytopenia | 56.12 | 16.65 | 31 | 16372 | 9651 | 79718334 |
| Agranulocytosis | 55.91 | 16.65 | 57 | 16346 | 44973 | 79683012 |
| Pancytopenia | 54.30 | 16.65 | 111 | 16292 | 165634 | 79562351 |
| Stevens-Johnson syndrome | 51.23 | 16.65 | 51 | 16352 | 39115 | 79688870 |
| Headache | 50.02 | 16.65 | 37 | 16366 | 653735 | 79074250 |
| Transplant rejection | 47.15 | 16.65 | 36 | 16367 | 19401 | 79708584 |
| Renal tubular necrosis | 45.14 | 16.65 | 39 | 16364 | 25000 | 79702985 |
| Joint swelling | 44.68 | 16.65 | 4 | 16399 | 288642 | 79439343 |
| Fatigue | 43.68 | 16.65 | 78 | 16325 | 929649 | 78798336 |
| Cholestasis | 40.89 | 16.65 | 52 | 16351 | 52057 | 79675928 |
| Toxic epidermal necrolysis | 40.67 | 16.65 | 48 | 16355 | 44533 | 79683452 |
| Rhinalgia | 40.37 | 16.65 | 16 | 16387 | 2351 | 79725634 |
| Clostridium difficile colitis | 40.31 | 16.65 | 41 | 16362 | 32242 | 79695743 |
| Blood creatinine increased | 38.53 | 16.65 | 93 | 16310 | 154964 | 79573021 |
| Dialysis | 37.91 | 16.65 | 31 | 16372 | 18431 | 79709554 |
| Acute generalised exanthematous pustulosis | 37.61 | 16.65 | 30 | 16373 | 17224 | 79710761 |
| Nasopharyngitis | 35.56 | 16.65 | 5 | 16398 | 253876 | 79474109 |
| Weight increased | 35.45 | 16.65 | 7 | 16396 | 277379 | 79450606 |
| Drug intolerance | 35.18 | 16.65 | 6 | 16397 | 264113 | 79463872 |
| Acute respiratory distress syndrome | 34.62 | 16.65 | 44 | 16359 | 44023 | 79683962 |
| Autoimmune haemolytic anaemia | 33.24 | 16.65 | 21 | 16382 | 8359 | 79719626 |
| Fall | 33.05 | 16.65 | 31 | 16372 | 487598 | 79240387 |
| Toxic skin eruption | 32.85 | 16.65 | 31 | 16372 | 22262 | 79705723 |
| Neutrophil count increased | 32.53 | 16.65 | 35 | 16368 | 29361 | 79698624 |
| Lymphocyte count abnormal | 32.22 | 16.65 | 12 | 16391 | 1491 | 79726494 |
| Rash | 32.09 | 16.65 | 216 | 16187 | 578142 | 79149843 |
| Prothrombin time prolonged | 31.84 | 16.65 | 27 | 16376 | 16872 | 79711113 |
| Intraocular pressure increased | 31.43 | 16.65 | 21 | 16382 | 9184 | 79718801 |
| Dermatitis exfoliative generalised | 30.87 | 16.65 | 19 | 16384 | 7222 | 79720763 |
| Febrile neutropenia | 29.97 | 16.65 | 110 | 16293 | 230889 | 79497096 |
| Hypotension | 29.74 | 16.65 | 173 | 16230 | 440144 | 79287841 |
| Abdominal discomfort | 28.72 | 16.65 | 8 | 16395 | 250719 | 79477266 |
| Neutrophil count decreased | 28.49 | 16.65 | 61 | 16342 | 93898 | 79634087 |
| Affective disorder | 28.46 | 16.65 | 19 | 16384 | 8300 | 79719685 |
| Haemodialysis | 28.19 | 16.65 | 26 | 16377 | 18142 | 79709843 |
| Respiratory distress | 27.85 | 16.65 | 46 | 16357 | 58293 | 79669692 |
| Renal impairment | 27.47 | 16.65 | 83 | 16320 | 157700 | 79570285 |
| Haemoglobin decreased | 27.34 | 16.65 | 104 | 16299 | 222015 | 79505970 |
| Linear IgA disease | 26.71 | 16.65 | 13 | 16390 | 3119 | 79724866 |
| Immune effector cell-associated neurotoxicity syndrome | 26.62 | 16.65 | 16 | 16387 | 5832 | 79722153 |
| Weight decreased | 25.96 | 16.65 | 21 | 16382 | 355177 | 79372808 |
| Rash morbilliform | 25.87 | 16.65 | 16 | 16387 | 6134 | 79721851 |
| Nephritis | 25.82 | 16.65 | 14 | 16389 | 4200 | 79723785 |
| Enterococcal infection | 25.45 | 16.65 | 23 | 16380 | 15637 | 79712348 |
| Acinetobacter infection | 25.11 | 16.65 | 12 | 16391 | 2765 | 79725220 |
| Blood alkaline phosphatase increased | 24.92 | 16.65 | 46 | 16357 | 63618 | 79664367 |
| Pain in extremity | 24.89 | 16.65 | 23 | 16380 | 364515 | 79363470 |
| Blood bilirubin increased | 24.86 | 16.65 | 47 | 16356 | 66185 | 79661800 |
| Subclavian artery occlusion | 24.77 | 16.65 | 6 | 16397 | 168 | 79727817 |
| Systemic candida | 24.60 | 16.65 | 16 | 16387 | 6690 | 79721295 |
| Interstitial lung disease | 24.26 | 16.65 | 64 | 16339 | 112536 | 79615449 |
| Pseudomonas infection | 23.32 | 16.65 | 25 | 16378 | 20878 | 79707107 |
| Aspartate aminotransferase increased | 23.26 | 16.65 | 72 | 16331 | 138569 | 79589416 |
| Pleural effusion | 23.05 | 16.65 | 74 | 16329 | 145188 | 79582797 |
| Rash erythematous | 22.94 | 16.65 | 42 | 16361 | 57727 | 79670258 |
| Anaphylactic reaction | 22.72 | 16.65 | 52 | 16351 | 83691 | 79644294 |
| Pseudomembranous colitis | 22.65 | 16.65 | 14 | 16389 | 5360 | 79722625 |
| Alanine aminotransferase increased | 22.42 | 16.65 | 79 | 16324 | 162491 | 79565494 |
| White blood cell count decreased | 22.21 | 16.65 | 87 | 16316 | 188201 | 79539784 |
| Pain | 21.95 | 16.65 | 73 | 16330 | 703729 | 79024256 |
| Petechiae | 21.90 | 16.65 | 24 | 16379 | 20541 | 79707444 |
| Dermatitis exfoliative | 21.85 | 16.65 | 18 | 16385 | 10811 | 79717174 |
| Neutrophilic dermatosis | 21.51 | 16.65 | 7 | 16396 | 583 | 79727402 |
| Insomnia | 21.25 | 16.65 | 12 | 16391 | 245158 | 79482827 |
| International normalised ratio increased | 21.23 | 16.65 | 51 | 16352 | 84670 | 79643315 |
| Hepatic failure | 21.21 | 16.65 | 42 | 16361 | 61170 | 79666815 |
| Musculoskeletal stiffness | 21.16 | 16.65 | 5 | 16398 | 175003 | 79552982 |
| Drug abuse | 20.99 | 16.65 | 4 | 16399 | 162687 | 79565298 |
| White blood cell count increased | 20.97 | 16.65 | 47 | 16356 | 74586 | 79653399 |
| Contusion | 20.66 | 16.65 | 3 | 16400 | 148773 | 79579212 |
| Leukocytosis | 20.38 | 16.65 | 34 | 16369 | 43421 | 79684564 |
| Uveitis | 20.33 | 16.65 | 21 | 16382 | 16809 | 79711176 |
| Staphylococcal infection | 20.20 | 16.65 | 40 | 16363 | 58255 | 79669730 |
| Aplasia pure red cell | 20.12 | 16.65 | 15 | 16388 | 7795 | 79720190 |
| Antibiotic level above therapeutic | 19.95 | 16.65 | 7 | 16396 | 733 | 79727252 |
| Drug ineffective | 19.72 | 16.65 | 136 | 16267 | 1080777 | 78647208 |
| Extravasation blood | 19.48 | 16.65 | 6 | 16397 | 418 | 79727567 |
| Hepatocellular injury | 19.40 | 16.65 | 35 | 16368 | 47558 | 79680427 |
| Hepatic function abnormal | 19.39 | 16.65 | 45 | 16358 | 73062 | 79654923 |
| Sinusitis | 19.33 | 16.65 | 8 | 16395 | 195493 | 79532492 |
| Blood culture positive | 19.11 | 16.65 | 15 | 16388 | 8414 | 79719571 |
| Spontaneous haematoma | 18.76 | 16.65 | 8 | 16395 | 1414 | 79726571 |
| Acanthosis | 18.51 | 16.65 | 6 | 16397 | 493 | 79727492 |
| Mucosal inflammation | 18.40 | 16.65 | 45 | 16358 | 75535 | 79652450 |
| Organ failure | 18.27 | 16.65 | 11 | 16392 | 4022 | 79723963 |
| Depression | 18.23 | 16.65 | 11 | 16392 | 216779 | 79511206 |
| Swelling | 18.22 | 16.65 | 11 | 16392 | 216700 | 79511285 |
| Schizophrenia | 18.17 | 16.65 | 19 | 16384 | 15421 | 79712564 |
| Aspergillus infection | 18.08 | 16.65 | 21 | 16382 | 19140 | 79708845 |
| Hepatic cytolysis | 18.07 | 16.65 | 25 | 16378 | 27126 | 79700859 |
| Purpura | 17.76 | 16.65 | 21 | 16382 | 19506 | 79708479 |
| Bone marrow failure | 17.63 | 16.65 | 35 | 16368 | 51072 | 79676913 |
| Haemolytic anaemia | 17.61 | 16.65 | 20 | 16383 | 17800 | 79710185 |
| Muscle spasms | 17.52 | 16.65 | 7 | 16396 | 174723 | 79553262 |
| Skin oedema | 17.21 | 16.65 | 8 | 16395 | 1733 | 79726252 |
| Neuralgic amyotrophy | 17.20 | 16.65 | 5 | 16398 | 285 | 79727700 |
| Bacteraemia | 17.19 | 16.65 | 27 | 16376 | 32797 | 79695188 |
| Gamma-glutamyltransferase increased | 17.15 | 16.65 | 36 | 16367 | 54644 | 79673341 |
| Moraxella infection | 17.08 | 16.65 | 6 | 16397 | 631 | 79727354 |
| Cytomegalovirus infection | 16.92 | 16.65 | 31 | 16372 | 42613 | 79685372 |
| Clostridium difficile infection | 16.90 | 16.65 | 31 | 16372 | 42654 | 79685331 |
| Cytarabine syndrome | 16.87 | 16.65 | 4 | 16399 | 102 | 79727883 |
| Treatment failure | 16.81 | 16.65 | 7 | 16396 | 170479 | 79557506 |
| SARS-CoV-2 test positive | 16.70 | 16.65 | 16 | 16387 | 11700 | 79716285 |
| Coagulopathy | 16.66 | 16.65 | 28 | 16375 | 35978 | 79692007 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01CG02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase inhibitors |
| FDA MoA | N0000000202 | beta Lactamase Inhibitors |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D065093 | beta-Lactamase Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| CHEBI has role | CHEBI:33281 | antibiotics |
| CHEBI has role | CHEBI:35441 | antiinfective agents |
| CHEBI has role | CHEBI:35625 | beta-lactamase inhibitors |
| FDA EPC | N0000175930 | beta Lactamase Inhibitor |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Abscess of liver | indication | 27916005 | |
| Acute pyelonephritis | indication | 36689008 | DOID:559 |
| Peritonitis | indication | 48661000 | |
| Bacterial pneumonia | indication | 53084003 | DOID:874 |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Appendicitis | indication | 74400008 | DOID:8337 |
| Abdominal abscess | indication | 75100008 | |
| Cholecystitis | indication | 76581006 | DOID:1949 |
| Infection due to Staphylococcus aureus | indication | 406602003 | |
| Bacterial cystitis | indication | 424551004 | |
| Nosocomial pneumonia | indication | 425464007 | |
| Ventilator-acquired pneumonia | indication | 429271009 | |
| Sepsis caused by Haemophilus influenzae | indication | 447685007 | |
| Sepsis caused by Serratia | indication | 449084002 | |
| Bacterial pyelonephritis | indication | 838353009 | |
| Staphylococcus Nosocomial Pneumonia | indication | ||
| Diabetic Foot Infection | indication | ||
| Complicated Skin and Skin Structure Staphylococcus Aureus Infection | indication | ||
| E. Coli Appendicitis | indication | ||
| E. Coli Endometritis | indication | ||
| E. Coli Complicated Appendicitis | indication | ||
| Inflammatory Disease of Female Pelvic Organs | indication | ||
| Complicated Skin and Skin Structure Infection | indication | ||
| E. Coli Peritonitis | indication | ||
| E. Coli Pelvic Inflammatory Disease | indication | ||
| Bacteroides Complicated Appendicitis | indication | ||
| Bacteroides Peritonitis | indication | ||
| Bacteroides Appendicitis | indication | ||
| Ecthyma gangrenosum | off-label use | 17732003 | |
| Infection of bone | off-label use | 111253001 | |
| Sepsis of the newborn | off-label use | 206376005 | |
| Diverticulitis of gastrointestinal tract | off-label use | 271366000 | |
| Pseudomonas Respiratory Tract Infection in Cystic Fibrosis | off-label use | ||
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Infectious mononucleosis | contraindication | 271558008 | DOID:8568 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.19 | acidic |
| pKa2 | 0.39 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ZOSYN | WYETH PHARMS | N050684 | Oct. 22, 1993 | DISCN | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 40MG BASE/ML;EQ 5MG BASE/ML | ZOSYN IN PLASTIC CONTAINER | BAXTER HLTHCARE CORP | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 40MG BASE/ML;EQ 5MG BASE/ML | ZOSYN IN PLASTIC CONTAINER | BAXTER HLTHCARE CORP | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 4GM BASE/100ML;EQ 500MG BASE/100ML | ZOSYN IN PLASTIC CONTAINER | BAXTER HLTHCARE CORP | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 4GM BASE/100ML;EQ 500MG BASE/100ML | ZOSYN IN PLASTIC CONTAINER | BAXTER HLTHCARE CORP | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 60MG BASE/ML;EQ 7.5MG BASE/ML | ZOSYN IN PLASTIC CONTAINER | BAXTER HLTHCARE CORP | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 6900184 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 60MG BASE/ML;EQ 7.5MG BASE/ML | ZOSYN IN PLASTIC CONTAINER | BAXTER HLTHCARE CORP | N050750 | Feb. 24, 1998 | RX | INJECTABLE | INJECTION | 8133883 | April 14, 2023 | METHOD OF TREATING BACTERIAL INFECTIONS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | METHODS FOR TREATING BACTERIAL INFECTIONS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 7129232 | May 15, 2028 | METHODS OF TREATING BACTERIAL ILLNESSES |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10028963 | Sept. 7, 2032 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10028963 | Sept. 7, 2032 | TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 9724353 | Sept. 7, 2032 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 9724353 | Sept. 7, 2032 | TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8685957 | Sept. 27, 2032 | METHODS OF TREATING BACTERIAL ILLNESSES |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10420841 | March 14, 2034 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 11278622 | March 14, 2034 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 11278622 | March 14, 2034 | TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD) |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 8968753 | March 14, 2034 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10376496 | Sept. 9, 2034 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10376496 | Sept. 9, 2034 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10933053 | Sept. 9, 2034 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | 10933053 | Sept. 9, 2034 | TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | Dec. 19, 2019 | NEW CHEMICAL ENTITY |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | Dec. 19, 2024 | GENERATING ANTIBIOTIC INCENTIVES NOW |
| EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | ZERBAXA | CUBIST PHARMS LLC | N206829 | Dec. 19, 2014 | RX | POWDER | INTRAVENOUS | April 21, 2025 | NEW PATIENT POPULATION |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-lactamase TEM | Enzyme | INHIBITOR | IC50 | 6.60 | WOMBAT-PK | CHEMBL | |||
| Beta-lactamase | Enzyme | IC50 | 6.29 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 6.53 | WOMBAT-PK | |||||
| Beta-lactamase | Enzyme | IC50 | 7.82 | WOMBAT-PK | |||||
| Beta-lactamase | Enzyme | IC50 | 5.47 | CHEMBL | |||||
| Beta-lactamase SHV-1 | Enzyme | IC50 | 6.65 | CHEMBL | |||||
| Beta-lactamase 1 | Enzyme | IC50 | 6.52 | DRUG MATRIX | |||||
| IMI-1; IMI-1 carbapenemase | Enzyme | IC50 | 7.52 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 7.22 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 6.09 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 6.72 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 6.03 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 7.40 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 8 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 8.40 | CHEMBL | |||||
| Carbapenem-hydrolizing beta-lactamase SFC-1 | Enzyme | IC50 | 5.16 | CHEMBL | |||||
| Carbepenem-hydrolyzing beta-lactamase KPC | Enzyme | Ki | 4.13 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 7.02 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 8.70 | CHEMBL | |||||
| Beta-lactamase SHV-1 | Enzyme | IC50 | 6.96 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 6.62 | CHEMBL | |||||
| Beta-lactamase GES-13 | Enzyme | IC50 | 7.22 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 7.10 | CHEMBL | |||||
| Class D beta-lactamase | Unclassified | IC50 | 6.80 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 6.30 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 8.66 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 5.70 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 5.70 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 7 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 7.40 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D00660 | KEGG_DRUG |
| 89785-84-2 | SECONDARY_CAS_RN |
| 4020843 | VANDF |
| C0075870 | UMLSCUI |
| CHEBI:9421 | CHEBI |
| TAZ | PDB_CHEM_ID |
| CHEMBL404 | ChEMBL_ID |
| DB01606 | DRUGBANK_ID |
| CHEMBL1439 | ChEMBL_ID |
| D000078142 | MESH_DESCRIPTOR_UI |
| 123630 | PUBCHEM_CID |
| 10789 | IUPHAR_LIGAND_ID |
| 6340 | INN_ID |
| SE10G96M8W | UNII |
| 221167 | RXNORM |
| 30782 | MMSL |
| 5543 | MMSL |
| d04404 | MMSL |
| 004398 | NDDF |
| 004399 | NDDF |
| 410931003 | SNOMEDCT_US |
| 427652008 | SNOMEDCT_US |
| 96007008 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8860 | INJECTION, SOLUTION | 250 mg | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8860 | INJECTION, SOLUTION | 250 mg | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8860 | INJECTION, SOLUTION | 250 mg | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8861 | INJECTION, SOLUTION | 375 mg | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8861 | INJECTION, SOLUTION | 375 mg | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8861 | INJECTION, SOLUTION | 375 mg | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8862 | INJECTION, SOLUTION | 500 mg | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8862 | INJECTION, SOLUTION | 500 mg | INTRAVENOUS | NDA | 27 sections |
| Zosyn in Galaxy Containers | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0206-8862 | INJECTION, SOLUTION | 500 mg | INTRAVENOUS | NDA | 27 sections |
| Zosyn | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0338-9632 | INJECTION, SOLUTION | 0.25 g | INTRAVENOUS | NDA | 29 sections |
| Zosyn | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0338-9636 | INJECTION, SOLUTION | 0.38 g | INTRAVENOUS | NDA | 29 sections |
| Zosyn | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0338-9638 | INJECTION, SOLUTION | 0.50 g | INTRAVENOUS | NDA | 29 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-2999 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1.50 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-2999 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1.50 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-2999 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1.50 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3374 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3374 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3374 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3378 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.38 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3378 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.38 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3378 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.38 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3379 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3379 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3379 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 25 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3383 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3383 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3383 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.25 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3385 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.38 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3385 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.38 g | INTRAVENOUS | ANDA | 26 sections |
| Piperacillin and Tazobactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-3385 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.38 g | INTRAVENOUS | ANDA | 26 sections |